• linkedin
  • Increase Font
  • Sharebar

    ADT plus salvage RT lowers PCa metastases, raises survival

    Framework may help clinicians individualize therapy to reduce side effect risk

    Badar M. Mian, MDBadar M. Mian, MD

    “Journal Article of the Month” is a new Urology Times section in which Badar M. Mian, MD (left), offers perspective on noteworthy research in the peer-reviewed literature.  Dr. Mian is associate professor of surgery in the division of urology at Albany Medical College, Albany, NY.


    A recent review of two phase III randomized controlled trials demonstrated that addition of androgen deprivation therapy (ADT) to salvage pelvic radiation therapy (RT) for prostate cancer recurrence after radical prostatectomy reduces the risk of metastases and improves overall survival.

    However, according to a clinical decision-making framework developed by the review’s authors (Eur Urol [epub ahead of print], July 14, 2017), an individualized approach provides the most benefit in patients with more adverse features such as higher PSA level or adverse pathology.

    Nearly one-third of men treated with radical prostatectomy will experience recurrent prostate cancer and are often treated with salvage radiation therapy. Addition of ADT to RT for the intact prostate has been shown to reduce the risk of recurrence or progression, but the use of ADT in the setting of salvage RT, while often used, has been poorly understood.

    Also by Dr. Mian: Most robotic RPs performed at low-volume hospitals

    The two trials have distinct features in terms of patient population, the type of ADT used, and outcomes. In the American study, RTOG 9601, bicalutamide (Casodex), 150 mg per day was used for 2 years along with salvage RT. The European study, GETUG-16, used hormone therapy with the LHRH analog goserelin (Zoladex) for 6 months. RTOG 9601 recruited patients with, on average, more adverse features such as higher PSA level, higher rate of positive surgical margins, persistently elevated PSA level, and higher Gleason score. Further, RTOG 9601 showed a lower risk of metastases and an overall survival advantage while GETUG-16 so far has only demonstrated a biochemical recurrence advantage from adding the hormone therapy to salvage RT.

    The authors highlight the differences and present a framework to enable clinicians to select the most appropriate patients for the combination of ADT with salvage RT. Because the benefit from the ADT was not demonstrated until the second decade, men with less than 10 years of life expectancy may be treated with salvage RT alone. In both trials, the largest benefit from ADT was noted in men with pre-salvage RT PSA >0.5 ng/mL or >0.7 ng/mL, so men with a higher PSA level may be better candidates for this combined approach. Similarly, men with higher grade cancers and positive surgical margins demonstrated lower risk of metastases and improved overall survival with the addition of ADT.

    Next: Side effects differ between studies


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available